Microbial diagnostics and wellness product developer uBiome has received series C funding in a Dentsu Ventures-backed round.
US-based microbial genomics technology developer uBiome has raised $83m in series C funding from investors including Dentsu Ventures, the corporate venturing vehicle formed by marketing firm Dentsu.
The round was led by venture capital fund OS Fund and included 8VC, Y Combinator and undisclosed new and existing investors. It increased the company’s funding to altogether.
Founded in 2012, uBiome is developing wellness products and diagnostics products focusing on diseases such as inflammatory bowel disease, cancer and metabolic disorders by harnessing…
